US 7560466
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
granted A61KA61K31/506A61K31/538
Quick answer
US patent 7560466 (Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds) held by Rigel Pharmaceuticals, Inc. expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Jul 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/506, A61K31/538, A61K31/541, A61P